35523-64-9

Basic information

• Product Name: 2,3-diamino-6-methylpyrimidin-4(3H)-one
• Synonyms: 2,3-Diamino-6-methylpyrimidin-4(3H)-one; 4(3H)-Pyrimidinone, 2,3-diamino-6-methyl-
• CAS NO: 35523-64-9
• Molecular Formula: C₅H₈N₄O
• Molecular Weight: 140.1432
• Mol File: 35523-64-9.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 301.9°C at 760 mmHg
• Flash Point: 136.4°C
• Density: 1.56g/cm³
• Vapor Pressure: 0.00102mmHg at 25°C
• Refractive Index: 1.695
• CAS DataBase Reference: 2,3-diamino-6-methylpyrimidin-4(3H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3-diamino-6-methylpyrimidin-4(3H)-one(35523-64-9)
• EPA Substance Registry System: 2,3-diamino-6-methylpyrimidin-4(3H)-one(35523-64-9)

Safety Data

• Hazardous Substances Data: 35523-64-9(Hazardous Substances Data)

Usage

General Description

2,3-diamino-6-methylpyrimidin-4(3H)-one is a chemical compound with the molecular formula C6H9N5O. It is a pyrimidine derivative with two amino groups and a methyl group attached to the pyrimidine ring. 2,3-diamino-6-methylpyrimidin-4(3H)-one has potential applications in the pharmaceutical industry, particularly in the development of antiviral and antimicrobial drugs. It has also been studied for its potential use in the synthesis of nucleoside analogs and as a building block for heterocyclic compounds. Additionally, 2,3-diamino-6-methylpyrimidin-4(3H)-one has been investigated for its potential use in the development of novel materials and as a tool for chemical research.

Upstream product

• 141-97-9 ethyl acetoacetate 
• 79-17-4 aminoguanidine 
• 1937-19-5 1-aminoguanidine hydrochloride 

Downstream Products

• 1281860-66-9 2-(1,1-difluoroethyl)-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-ol 
• 28565-42-6 7-chloro-2-ethyl-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidine 
• 1282041-90-0 2-ethyl-5-methyl-N-[4-(pentafluoro-λ6-sulfanyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine 
• 1281860-97-6 5-methyl-2-(1-methylethyl)-N-[4-(trifluoromethyl)phenyl][1,2,4]-triazolo[1,5-a]pyrimidin-7-amine 
• 1282041-92-2 5-methyl-2-(1-methylethyl)-N-[4-(pentafluoro-λ6-sulfanyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine 
• 1281861-00-4 2-cyclopropyl-5-methyl-N-[4-(trifluoromethyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine 
• 1282041-93-3 2-cyclopropyl-5-methyl-N-[4-(pentafluoro-λ6-sulfanyl)phenyl]-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine 
• 1282041-94-4 2-(1,1-difluoroethyl)-5-methyl-N-[4-(pentafluoro-λ⁶-sulfanyl)phenyl]-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine 
• 1281861-06-0 2-(1,1-difluoroethyl)-5-methyl-N-[4-(trifluoromethyl)phenyl]-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine 
• 1281861-07-1 2-(1,1-difluoroethyl)-N-[3-fluoro-4-(trifluoromethyl)phenyl]-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine 
• 1281861-08-2 N-(3,5-difluoro-4-(trifluoromethyl)phenyl)-2-(1,1-difluoroethyl)-5-methyl[1,2,4]triazolo-[1,5-a]pyrimidin-7-amine 
• 1281861-09-3 2-(1,1-difluoropropyl)-5-methyl-N-[4-(trifluoromethyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine 
• 1282041-95-5 2-(1,1-difluoropropyl)-5-methyl-N-[4-(pentafluoro-λ6-sulfanyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine 
• 1315606-94-0 5-methyl-2-[2-(methyloxy)ethyl]-N-[4-(pentafluoro-λ6-sulfanyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine 

Relevant articles and documents

FERROCHELATASE INHIBITORS AND METHODS OF USE

The invention relates to a method of treatment of a patient with a ferrochelatase inhibitor, or a pharmaceutically acceptable salt thereof, or a derivative thereof. Also, the invention relates to a method of treatment of a patient with a ferrochelatase in

Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential

Drug therapy is the mainstay of antimalarial therapy, yet current drugs are threatened by the development of resistance. In an effort to identify new potential antimalarials, we have undertaken a lead optimization program around our previously identified triazolopyrimidine-based series of Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitors. The X-ray structure of PfDHODH was used to inform the medicinal chemistry program allowing the identification of a potent and selective inhibitor (DSM265) that acts through DHODH inhibition to kill both sensitive and drug resistant strains of the parasite. This compound has similar potency to chloroquine in the humanized SCID mouse P. falciparum model, can be synthesized by a simple route, and rodent pharmacokinetic studies demonstrated it has excellent oral bioavailability, a long half-life and low clearance. These studies have identified the first candidate in the triazolopyrimidine series to meet previously established progression criteria for efficacy and ADME properties, justifying further development of this compound toward clinical candidate status.

Formation, structure and heterocyclization of aminoguanidine and ethyl acetoacetate condensation products

Condensation of aminoguanidine hydrochloride and ethyl acetoacetate results in 2,3-diamino-6-methylpyrimidin-4(3H)-one, 5-hydroxy-1-carboxamidino-3- methylpyrazole or ethyl N-[(5-hydroxy-3-methylpyrazol-1-yl)imidoyl] aminocrotonoate depending on the type of the base. Formation of pyrazole derivatives occurs in the case of dequaternized substrate imine-group protonating by the acids formed as a result of ion exchange reaction. Chelate fragment of amidinohydroxypyrazole structure provides stabilization of this compound and stipulates its inertness towared the heterocycle closure.